InspireMD EBIT

The latest EBIT for NSPR is $-48M as of December 2025. That compares with $-34M in the prior-year period — down 44.6% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside InspireMD's historical trend and sector peers before judging valuation or financial health.

Over the past year, NSPR's EBIT moved from $-34M to $-48M — a 44.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InspireMD's operating scale or balance-sheet position.

Against Healthcare companies, NSPR currently prints $-48M for EBIT, while the sector average sits near $22B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at InspireMD's growth, margins, and balance sheet.

A EBIT figure of $-48M for NSPR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting NSPR's EBIT ($-48M), review year-over-year change from $-34M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.